The human topoisomerase 1B Arg634Ala mutation results in camptothecin resistance and loss of inter-domain motion correlation

Biochim Biophys Acta. 2013 Dec;1834(12):2712-21. doi: 10.1016/j.bbapap.2013.09.017. Epub 2013 Oct 2.

Abstract

Human topoisomerase 1B, the unique target of the natural anticancer compound camptothecin, catalyzes the unwinding of supercoiled DNA by introducing transient single strand nicks and providing covalent protein-DNA adducts. The functional properties and the drug reactivity of the single Arg634Ala mutant have been investigated in comparison to the wild type enzyme. The mutant is characterized by an identical relaxation and cleavage rate but it displays resistance to camptothecin as indicated by a viability assay of the yeast cells transformed with the mutated protein. The mutant also displays a very fast religation rate that is only partially reduced by the presence of the drug, suggesting that this is the main reason for its resistance. A comparative analysis of the structural-dynamical properties of the native and mutant proteins by molecular dynamics simulation indicates that mutation of Arg634 brings to a loss of motion correlation between the different domains and in particular between the linker and the C-terminal domain, containing the catalytic tyrosine residue. These results indicate that the loss of motion correlation and the drug resistance are two strongly correlated events.

Keywords: BSA; CPT; Camptothecin; DMSO; DTT; EDTA; EGTA; Linker domain; Molecular dynamics; PMSF; Single mutation; TBE; TPT; Topoisomerase; bovine serine albumin; camptothecin; dimethyl sulfoxide; dithiothreitol; ethylene glycol tetraacetic acid; ethylenediaminetetraacetic acid; hTop1B; human topoisomerase 1B; phenylmethanesulfonylfluoride; topotecan; tris-borate-EDTA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Camptothecin / chemistry*
  • Camptothecin / pharmacology
  • DNA Topoisomerases, Type I* / chemistry
  • DNA Topoisomerases, Type I* / genetics
  • DNA Topoisomerases, Type I* / metabolism
  • Drug Resistance, Neoplasm*
  • Humans
  • Molecular Dynamics Simulation*
  • Mutation, Missense*
  • Protein Structure, Tertiary
  • Saccharomyces cerevisiae / enzymology
  • Saccharomyces cerevisiae / genetics
  • Topoisomerase I Inhibitors / chemistry*
  • Topoisomerase I Inhibitors / pharmacology

Substances

  • Topoisomerase I Inhibitors
  • DNA Topoisomerases, Type I
  • TOP1 protein, human
  • Camptothecin